Clinical Trials on Non-Alcoholic Steatohepatitis in Austria

Total 1232 results

Novo Nordisk A/S

Recruiting

A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children.

Healthy Volunteers (Non-alcoholic Steatohepatitis)

Austria
Inipharm Australia Pty Ltd

Recruiting

A Study of INI-822 in Healthy Volunteers and Participants With Non-alcoholic Steatohepatitis (NASH) or Presumed NASH

Non-alcoholic Steatohepatitis

Australia
LISCure Biosciences

Completed

A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants

Rheumatoid Arthritis | Non-Alcoholic Steatohepatitis

Australia
Dongguan HEC Biopharmaceutical R&D Co., Ltd.

Completed

The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects

Non-alcoholic Steatohepatitis

Australia
Novartis Pharmaceuticals

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

Non-alcoholic Steatohepatitis NASH

United Kingdom, United States, Australia, New Zealand, Switzerland, Jordan, Georgia, Puerto Rico
Altimmune, Inc.

Recruiting

Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial) (IMPACT)

Non-Alcoholic Steatohepatitis (NASH)

Australia, United States, Puerto Rico
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH) (FLIGHT-FXR)

Non-alcoholic Steatohepatitis (NASH)

Belgium, Germany, Taiwan, Austria, United States, Spain, Korea, Republic of, Argentina, Australia, Italy, Japan, Singapore, Netherlands, Slovakia, France, Canada, India
Immuron Ltd.

Completed

A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Non-alcoholic Steatohepatitis (NASH)

United States, Australia, Israel
Inventiva Pharma

Completed

Phase 2b Study in NASH to Assess IVA337 (NATIVE)

Non-Alcoholic Steatohepatitis (NASH)

United States, Spain, United Kingdom, France, Belgium, Austria, Switzerland, Australia, Germany, Slovenia, Bulgaria, Canada, Czechia, Italy, Mauritius, Poland
NorthSea Therapeutics B.V.

Active, not recruiting

A Phase 2b Study of Icosabutate in Fatty Liver Disease (ICONA)

Non Alcoholic Steatohepatitis (NASH)

United States, Puerto Rico
Enanta Pharmaceuticals, Inc
ICON Clinical Research; Triangle Biostatistics

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

Non-Alcoholic Steatohepatitis

United States, United Kingdom, New Zealand, Canada, France, Puerto Rico
Medical University of Vienna
State Government of Vienna, Austria (Medizinisch-Wissenschaftlicher Fonds...

Completed

Impact of Fructose Consumption on Intestinal Permeability in Non-alcoholic Fatty Liver Disease (NAFLD) - a Pilot Study.

Non-alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis

Austria
Enanta Pharmaceuticals, Inc

Terminated

A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Non-Alcoholic Steatohepatitis

United States, Canada, Puerto Rico, United Kingdom, Argentina, Germany
Dr. Falk Pharma GmbH

Recruiting

Norursodeoxycholic Acid vs. Placebo in NASH

Nonalcoholic Steatohepatitis

Austria
Boehringer Ingelheim

Completed

A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

Non-alcoholic Steatohepatitis (NASH)

United States, Spain, Korea, Republic of, United Kingdom, Australia, Canada, Singapore, Germany, Italy, Malaysia, China, France, Japan, Taiwan, Netherlands, Austria, Israel, New Zealand, Poland, Hong Kong, Belgium, Czechia, Greece, Hu... and more
RWTH Aachen University

Completed

Dietary Modulation of Intestinal Microbiota as Trigger of Liver Health: Role of Bile Acids - "A Diet for Liver Health" (ADLH)

NASH - Nonalcoholic Steatohepatitis

Sweden, Austria, Germany
AstraZeneca

Recruiting

A Trial to Learn How Safe AZD9550 is in People With Type 2 Diabetes Who Are Overweight or Obese (CONTEMPO)

Non-alcoholic Steatohepatitis (NASH)

Austria, Germany, Japan, Sweden
AstraZeneca

Completed

A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis (PROXYMO-ADV)

Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

United States, Austria, Italy, Thailand, Germany, Korea, Republic of, Japan, Malaysia, New Zealand, Spain, Taiwan, Turkey, Australia, Israel, Argentina, Canada, Greece, South Africa, United Kingdom, France
Axcella Health, Inc

Recruiting

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

Non Alcoholic Steatohepatitis (NASH)

United States, Canada, United Kingdom, Australia, France, Poland, Puerto Rico
Intercept Pharmaceuticals

Terminated

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

Non Alcoholic Steatohepatitis (NASH)

United States, Finland, France, Spain, United Kingdom, Israel, Austria, Italy, Denmark, Germany, Belgium, Switzerland, Puerto Rico, Poland, Australia, Sweden, Serbia, New Zealand, Canada, Hungary, Portugal
Prof. Michael Trauner, MD
Wiener Wissenschafts-, Forschungs- und Technologiefonds

Unknown

Unravelling Mechanisms of Fructose vs Glucose Consumption in the Pathogenesis and Progression of NAFLD

Non-alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis

Austria
Altimmune, Inc.

Completed

ALT-801 DDI Study in Healthy Volunteers

NASH - Nonalcoholic Steatohepatitis

Australia
Sagimet Biosciences Inc.

Completed

Study of TVB 2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Fatty Liver Disease

China, United States
Mirum Pharmaceuticals, Inc.

Terminated

Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis

United States, United Kingdom, Canada, Puerto Rico
Medical University of Vienna

Recruiting

Gut Permeability and Bariatric-metabolic Surgery

Bariatric Surgery Candidate | NASH - Nonalcoholic Steatohepatitis | Intestinal Permeability

Austria
JD Bioscience Inc.
Novotech (Australia) Pty Limited

Enrolling by invitation

First-in-Human Study of GM-60106 in Healthy Adults and Otherwise Healthy Adults With an Increased Body Mass Index and Markers of Non-Alcoholic Fatty Liver Disease

Non-alcoholic Steatohepatitis

Australia
Enyo Pharma

Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

United States, Belgium, France, Puerto Rico, United Kingdom
Novo Nordisk A/S

Active, not recruiting

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

Spain, Denmark, Taiwan, Korea, Republic of, Australia, Canada, India, Singapore, United States, Turkey, Poland, Italy, Belgium, Puerto Rico, United Kingdom, Malaysia, Germany, Portugal, Bulgaria, Czechia, France, Greece, Japan, Russian...
Genentech, Inc.

Terminated

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis (BANFF)

Non-alcoholic Steatohepatitis

Belgium, United States, Spain, Puerto Rico, France
Novo Nordisk A/S

Completed

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Non-alcoholic Steatohepatitis | Hepatobiliary Disorders

United States, Russian Federation, United Kingdom, Denmark, Sweden, Netherlands, Austria, Belgium, Spain, France, Bulgaria, Canada, Australia, Greece, Japan, Finland, Puerto Rico
Enyo Pharma

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients

Healthy | NASH - Nonalcoholic Steatohepatitis

Australia
Sunshine Lake Pharma Co., Ltd.

Completed

The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Subjects

Non-alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis

Australia
Syneos Health

Completed

First-in-Human Study of SRT-015 in Healthy Subjects.

Nonalcoholic Steatohepatitis

Australia
Eccanga Pty Ltd
Syneos Health

Recruiting

FTIH Study of ECC0509 in Healthy Volunteers

Osteoarthritis | Nonalcoholic Steatohepatitis

Australia
Novo Nordisk A/S

Recruiting

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) (ESSENCE)

Non-alcoholic Steatohepatitis

United States, Korea, Republic of, Australia, Taiwan, Italy, Israel, Canada, Netherlands, Czechia, Malaysia, Spain, Denmark, China, United Kingdom, Singapore, Japan, Puerto Rico, Portugal, Ireland, Belgium, Romania, Germany, Russian... and more
Rivus Pharmaceuticals, Inc.

Recruiting

Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

Fatty Liver | Nonalcoholic Steatohepatitis | Non-Alcoholic Fatty Liver Disease

United States
Blade Therapeutics

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects

NASH - Nonalcoholic Steatohepatitis | Chronic Liver Disease

Australia
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States, Australia, Puerto Rico
Corcept Therapeutics

Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Corcept Therapeutics

Active, not recruiting

A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Cascade Pharmaceuticals, Inc
Laboratory Corporation of America

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH

Nonalcoholic Steatohepatitis (NASH)

United States
Altimmune, Inc.

Completed

ALT-801 in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

NASH - Nonalcoholic Steatohepatitis

Australia
Corcept Therapeutics

Terminated

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Second Genome

Terminated

Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis

United States
Poxel SA

Completed

Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)

NASH - Nonalcoholic Steatohepatitis

United States
Terns, Inc.

Completed

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis

United States
Akero Therapeutics, Inc

Active, not recruiting

A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) (Harmony)

NASH - Nonalcoholic Steatohepatitis

United States, Puerto Rico
Corcept Therapeutics

Recruiting

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Nonalcoholic Steatohepatitis (NASH) | Metabolic Dysfunction-associated Steatohepatitis (MASH)

United States, Puerto Rico
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (ATLAS)

Nonalcoholic Steatohepatitis

Hong Kong, United States, Australia, Puerto Rico, New Zealand, Canada
Madrigal Pharmaceuticals, Inc.

Active, not recruiting

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH)

NASH - Nonalcoholic Steatohepatitis

United States, Spain, Australia, United Kingdom, Canada, Israel, Belgium, Italy, France, Puerto Rico, Switzerland, Germany, Austria, Poland, Mexico, Hungary

Clinical Trials on Non-Alcoholic Steatohepatitis in Austria

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations